{"id":538619,"date":"2021-04-14T19:30:01","date_gmt":"2021-04-14T19:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538619"},"modified":"2021-04-14T19:30:01","modified_gmt":"2021-04-14T19:30:01","slug":"diabetes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-daewoong-tradipitant-janssen-biotech-zealand-pharma-provention-bio-imcyse-novo-nordisk-enthera-actobio-th","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-daewoong-tradipitant-janssen-biotech-zealand-pharma-provention-bio-imcyse-novo-nordisk-enthera-actobio-th_538619.html","title":{"rendered":"Diabetes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, ImCyse, Novo Nordisk, Enthera, ActoBio Th"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, ImCyse, Novo Nordisk, Enthera, ActoBio Th\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Diabetes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, ImCyse, Novo Nordisk, Enthera, ActoBio Th\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Diabetes Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Diabetes Pipeline<\/a> Insights, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about <strong>200+ companies and 200+ pipeline drugs<\/strong> in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetes<\/strong>, is a metabolic disease that causes high blood sugar. The hormone insulin moves sugar from the blood into your cells to be stored or used for energy. With diabetes, your body either doesn&rsquo;t make enough insulin or can&rsquo;t effectively use the insulin it does make.<\/p>\n<p style=\"text-align: justify;\">Untreated high blood sugar from diabetes can damage your nerves, eyes, kidneys, and other organs.<\/p>\n<p style=\"text-align: justify;\">There are a few different types of diabetes:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Type 1 diabetes&nbsp;is an&nbsp;autoimmune disease. The immune system attacks and destroys cells in the&nbsp;pancreas, where insulin is made. It&rsquo;s unclear what causes this attack. About&nbsp;10 percent&nbsp;of people with diabetes have this type.<\/li>\n<li>Type 2 diabetes&nbsp;occurs when your body becomes resistant to&nbsp;insulin, and sugar builds up in your blood.<\/li>\n<li>Prediabetes&nbsp;occurs when your blood sugar is higher than normal, but it&rsquo;s not high enough for a diagnosis of type 2 diabetes.<\/li>\n<li>Gestational diabetes&nbsp;is high blood sugar during pregnancy. Insulin-blocking hormones produced by the placenta cause this type of diabetes.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free Sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Diabetes Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Daewoong Tradipitant<\/li>\n<li>Janssen Biotech<\/li>\n<li>Zealand Pharma<\/li>\n<li>Provention Bio<\/li>\n<li>BioRestorative Therapies<\/li>\n<li>Elevian<\/li>\n<li>Kamada<\/li>\n<li>Adocia<\/li>\n<li>Oramed Pharmaceuticals<\/li>\n<li>ImCyse<\/li>\n<li>Histogen<\/li>\n<li>Novo Nordisk<\/li>\n<li>Enthera<\/li>\n<li>ActoBio Therapeutics<\/li>\n<li>Japan Tobacco<\/li>\n<li>Avotres<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free Sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Diabetes Therapies<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Enavogliflozin<\/li>\n<li>Golimumab<\/li>\n<li>Dasiglucagon<\/li>\n<li>Teplizumab<\/li>\n<li>BRTX-100<\/li>\n<li>rGDF11<\/li>\n<li>Alpha-1 antitrypsin<\/li>\n<li>BC 222 Insulin Lispro<\/li>\n<li>Insulin oral<\/li>\n<li>IMCY-0098<\/li>\n<li>Emricasan<\/li>\n<li>Insulin icodec<\/li>\n<li>ENT-001<\/li>\n<li>AG019<\/li>\n<li>JTT-662<\/li>\n<li>AVT-001<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free Sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Diabetes: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Diabetes &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Diabetes Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Enavogliflozin: Daewoong<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Golimumab: Janssen Biotech<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase II\/I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">IMCY-0098: ImCyse<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">ENT-001: Enthera<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Diabetes Key Companies<\/p>\n<p style=\"text-align: justify;\">Diabetes Key Products<\/p>\n<p style=\"text-align: justify;\">Diabetes- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Diabetes- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Diabetes- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Diabetes Analyst Views<\/p>\n<p style=\"text-align: justify;\">Diabetes Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/diabetes-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-daewoong-tradipitant-janssen-biotech-zealand-pharma-provention-bio-imcyse-novo-nordisk-enthera-actobio-th\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-daewoong-tradipitant-janssen-biotech-zealand-pharma-provention-bio-imcyse-novo-nordisk-enthera-actobio-th\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetes Pipeline DelveInsight&rsquo;s,&nbsp;&ldquo;Diabetes Pipeline Insights, 2021,&rdquo;&nbsp;report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-daewoong-tradipitant-janssen-biotech-zealand-pharma-provention-bio-imcyse-novo-nordisk-enthera-actobio-th_538619.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-538619","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538619"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}